# Clinical Study on Wuling Powder in Treating Metabolic Syndrome of Spleen Deficiency and Dampness

> **NCT04812236** · PHASE4 · UNKNOWN · sponsor: **Jiangsu Famous Medical Technology Co., Ltd.** · enrollment: 320 (estimated)

## Conditions studied

- Metabolic Syndrome

## Interventions

- **DRUG:** Wulingsan single decoction granules
- **DRUG:** Wulingsan co-decoction granules
- **DRUG:** Wuling Powder
- **DRUG:** Wulingsan granule simulant

## Key facts

- **NCT ID:** NCT04812236
- **Lead sponsor:** Jiangsu Famous Medical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-01
- **Primary completion:** 2023-02-28
- **Final completion:** 2023-05-01
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2021-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04812236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04812236, "Clinical Study on Wuling Powder in Treating Metabolic Syndrome of Spleen Deficiency and Dampness". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04812236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*